TITLE

Generic drugs offer employers untapped savings

AUTHOR(S)
Anderson, Tom
PUB. DATE
December 2005
SOURCE
Employee Benefit News;Dec2005, Vol. 19 Issue 15, p44
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the savings on health care costs offered by alternative generic drugs. According to Express Scripts, consumers could have saved $20 billion in 2004 by using generic prescription drugs. A generic drug costs about 60% less than a brand-name drug. Employers and insurer are increasing incentives to members to use generic drugs and to physicians to prescribe them as non-brand treatments come on the market. Employers need to examine their pharmacy usage and study where generic alternatives can make an impact on cost.
ACCESSION #
19164355

 

Related Articles

  • Companiesandmarkets.com: Global Generics Market Bolstered by Value-Added 'Supergenerics.'.  // Biomedical Market Newsletter;10/24/2011, Vol. 21, p19 

    The article focuses on a report regarding the global market of generic drugs from 2011-2016. The reports showed that the generic drugs market is expanding at a robust rate, attributed to the increased focus on cost cutting measures in the world's medical and healthcare settings. The other...

  • The Economic Consequences of Generic Substitution for Antiepileptic Drugs in a Public Payer Setting: The Case of Lamotrigine. Duh, Mei Sheng; Andermann, Frederick; Paradis, Pierre Emmanuel; Weiner, Jennifer; Manjunath, Ranjani; Crémieux, Pierre-Yves // Disease Management;Aug2007, Vol. 10 Issue 4, p216 

    Generic substitution of antiepileptic drugs (AEDs) may increase pharmacy utilization, thus counterbalancing per-pill savings. The purpose of our study was to analyze the economic impact of government-mandated switching from branded to generic lamotrigine. Patients in a Canadian public pharmacy...

  • The population bomb. Richardson, John // ICIS Chemical Business;9/29/2008, Vol. 274 Issue 12, p28 

    The article discusses the demand for generic drugs in Japan, courtesy of the collision of an aging population and increasing drug costs in 2008. Japan Generic Pharmaceutical Manufacturers Association (JGPMA) stated the country's health care bill already amounts to ¥30 trillion, of which ¥6...

  • Analyzing generic and branded substitution patterns in the Netherlands using prescription data. Pechlivanoglou, Petros; van der Veen, Willem Jan; Bos, Jens H.; Postma, Maarten J. // BMC Health Services Research;2011, Vol. 11 Issue 1, p89 

    Background: As in other societies, pharmaceutical expenditures in the Netherlands are rising every year. As a consequence, needs for cost control are often expressed. One possible solution for cost control could come through increasing generic substitution by pharmacists. We aim to analyse the...

  • Analyzing generic and branded substitution patterns in the Netherlands using prescription data. Pechlivanoglou, Petros; van der Veen, Willem Jan; Bos, Jens H.; Postma, Maarten J. // BMC Health Services Research;2011, Vol. 11 Issue 1, p89 

    Background: As in other societies, pharmaceutical expenditures in the Netherlands are rising every year. As a consequence, needs for cost control are often expressed. One possible solution for cost control could come through increasing generic substitution by pharmacists. We aim to analyse the...

  • Generic substitution of clozapine not necessarily cost saving.  // PharmacoEconomics & Outcomes News;6/19/2005, Issue 455, p6 

    Focuses on a study which evaluated the cost effectiveness of generic substitution of clozapine. Estimated annual cost savings from switching a patient from brandname to generic clozapine; Net savings if a relapse incidence for switching was assumed.

  • Kostenreduktion durch projektgestützte Verschreibung von ACE-Hemmer Generika. Wolzt, Michael; Ohrenberger, Gerald; Reichardt, Berthold // Wiener Klinische Wochenschrift;2003, Vol. 115 Issue 1/2, p23 

    Background: Increasing drug costs are an economic burden for the health insurance system. Aim: The regional drug prescription pattern for ACE inhibitors in the Austrian county Burgenland was compared for patients discharged from hospital and those in primary care. Furthermore, the potential cost...

  • Generics poised for further consolidation. Mirasol, Feliza // Chemical Market Reporter;3/28/2005, Vol. 267 Issue 13, p38 

    Reports that generics companies are experiencing both the benefits and the risks of going up against branded pharmaceuticals. Push toward less-expensive but quality-grade prescription drugs; Political advocacy for the containment of health care costs; More-favorable legislation and policies in...

  • Trimming Those Healthcare Bills. Gearon, Christopher J.; Landau, Meryl Davids // U.S. News Digital Weekly;12/9/2011, Vol. 3 Issue 49, p22 

    This article discusses the issue of saving on medical expenses, relative to the entry of generic alternatives, particularly on the expensive drugs market of which patents have expired. It mentions that the expiration of patents of brand-name drugs starting 2012 up to 2015, will see the filling...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics